Literature DB >> 12651764

Anti B cell targeted immunotherapy for treatment of refractory autoimmune haemolytic anaemia in a young infant.

P C Ng1, K K M Lee, A F C Lo, C K Li, T F Fok.   

Abstract

We report the case of an 8 week old infant with fulminant autoimmune haemolytic anaemia refractory to conventional immunomodulating treatment. Massive haemolysis resulted in cardiac decompensation and acute renal failure which necessitated mechanical ventilation and peritoneal dialysis. Rituximab, a chimeric anti-CD20 monoclonal antibody, halted progression of the haemolytic process, but the patient died of acute viral pneumonia and disseminated fungal infection. Earlier introduction of rituximab might have prevented the renal complications. Paediatricians should be aware of this useful therapeutic tool for treatment of refractory autoimmune haemolytic anaemia and balance its use against the risk of potential life threatening infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12651764      PMCID: PMC1719511          DOI: 10.1136/adc.88.4.337

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  5 in total

Review 1.  Treatment with rituximab in benign and malignant hematologic disorders in children.

Authors:  Lisa B Giulino; James B Bussel; Ellis J Neufeld
Journal:  J Pediatr       Date:  2007-04       Impact factor: 4.406

2.  Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab.

Authors:  Kousaku Matsubara; Yoshiyuki Takahashi; Akira Hayakawa; Fumiko Tanaka; Hisaya Nakadate; Michio Sakai; Naoko Maeda; Toshiaki Oka; Eiichi Ishii; Fumio Bessho; Tsuyoshi Morimoto; Hiroaki Goto; Yoshiko Hashii; Naoki Hatakeyama; Akira Shirahata; Masue Imaizumi
Journal:  Int J Hematol       Date:  2014-03-08       Impact factor: 2.490

Review 3.  The long-term impact of rituximab for childhood immune thrombocytopenia.

Authors:  Nichola Cooper; James B Bussel
Journal:  Curr Rheumatol Rep       Date:  2010-04       Impact factor: 4.592

Review 4.  Treatment Options for Primary Autoimmune Hemolytic Anemia: A Short Comprehensive Review.

Authors:  Abdulgabar Salama
Journal:  Transfus Med Hemother       Date:  2015-08-10       Impact factor: 3.747

5.  Cholestatic liver disease after rituximab and adalimumab and the possible role of cross-reacting antibodies to Fab 2 fragments.

Authors:  Joerg Latus; Reinhild Klein; Ina Koetter; Matthias Schwab; Peter Fritz; Martin Kimmel; M Dominik Alscher; Niko Braun
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.